Additive Manufacturing Market to Register CAGR of 20.8%, Attributed to Growing Demand for Prototype Applications from Different Industries
October 11, 2024 08:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Oct. 11, 2024 (GLOBE NEWSWIRE) -- SkyQuest projects that the Global Additive Manufacturing Market will reach a value of USD 91.59 Billion by 2031, with a CAGR of 20.8% during the...
Unaudited consolidated interim accounts for the third quarter and first nine months of 2024
October 10, 2024 09:30 ET
|
TKM Grupp AS
Segments (EURm)Q3/24Q3/23yoy9m/249m/23yoySupermarkets149.5153.5-2.6%446.3455.2-1.9%Department stores21.523.9-9.7%71.075.6-6.1%Cars50.751.1-0.8%149.6148.60.7%Security...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients
October 10, 2024 04:42 ET
|
Janssen Cilag International NV
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1 Data showed...
Amino Acids Market Size to Worth Around USD 69.11 Billion by 2034
October 08, 2024 06:22 ET
|
Precedence Research
Los Angeles, Oct. 08, 2024 (GLOBE NEWSWIRE) -- According to Precedence Research, the global amino acids market size will hit USD 33.72 billion in 2025 and is expected to surpass around USD 69.11...
WINFARM : First-half 2024 results.
October 03, 2024 12:00 ET
|
Winfarm
PRESS RELEASE Loudéac, 3 October 2024 FIRST-HALF 2024 RESULTS Return to growth in Q2 2024Gross margin holds up well at 32.4% of revenueOperating profitability bottoming out H2 2024 OUTLOOK ...
European Commission approves Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
September 30, 2024 04:58 ET
|
Janssen Cilag International NV
With this approval, Yuvanci® is the only single tablet combination therapy for treatment for patients with PAH in Europe Johnson & Johnson’s comprehensive PAH portfolio now covers all...
DARZALEX® (daratumumab) subcutaneous (SC) formulation-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned
September 27, 2024 13:05 ET
|
Janssen Cilag International NV
Study demonstrates a minimal residual disease (MRD)-negativity rate of 60.9 percent and 43 percent reduction in the risk of progression or death1 Phase 3 CEPHEUS study results presented in...
TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
September 27, 2024 08:21 ET
|
Janssen Cilag International NV
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific...
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
September 27, 2024 08:21 ET
|
Janssen Cilag International NV
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) --...
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
September 20, 2024 07:40 ET
|
Janssen Cilag International NV
Recommendation supported by findings from quadruplet therapy PERSEUS study with daratumumab subcutaneous (SC) formulation in the frontline setting Findings showed 60 percent reduction in risk...